The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14 months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel mult...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Ina Patties, Sonja Kallendrusch, Lisa B öhme, Eva Kendzia, Henry Oppermann, Frank Gaunitz, Rolf-Dieter Kortmann and Annegret Glasow Tags: Research Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Neurology | Nutrition | Radiation Therapy | Temodar